Li Huang

Senior Research Fellow

University of Melbourne
Country flagAustralia

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (17)

Introduction In 2014, multiple states expanded Medicaid coverage to low-income adults under the Affordable Care Act. We evaluated the association of Medicaid expansion (ME) with children's insurance coverage and health service utilization. Methods We compared changes in children's insurance coverage and health service utilization between 2010-2013 and 2014-2016 in expansion and non-expansion states. Repeated cross-sectional analysis with linear difference-in-differences (DID) models was conducted using the Medical Expenditure Panel Survey. Results Medicaid expansion was not associated with changes in the proportion of children with ≥1 month of insurance coverage (DID: −1.9% point [pp], 95% CI −4.1 to 0.3) or the proportion of children with continuous coverage for 12 months (DID: −1.8 pp, 95% CI −5.6 to 2.0). Expansion was not associated with changes in any utilization outcome, including having ≥1 annual well-child visit (DID: −1.9 pp, 95% CI −6.6 to 2.8) or ≥1 annual dental visit (DID: 1.9 pp, 95% CI −2.8 to 6.5). Conclusion Medicaid expansion was not associated with changes in children's coverage and utilization. While policymakers in states that have not yet expanded Medicaid might still consider doing so for other reasons, findings suggest that alternative interventions will be needed to improve coverage and utilization patterns in children.

Year:

2026

Year:

2025

Background and Objective Genomic medicine offers an unprecedented opportunity to improve cancer outcomes through prevention, early detection and precision therapy. Health policy makers worldwide are developing strategies to embed genomic medicine in routine cancer care. Successful translation of genomic medicine, however, remains slow. This systematic review aims to identify and synthesise published evidence on the cost effectiveness of genomic medicine in cancer control. The insights could support efforts to accelerate access to cost-effective applications of human genomics. Methods The study protocol was registered with PROSPERO (CRD42024480842), and the review was conducted in line with Preferred Reporting Items for Systematic Reviews and Meta Analyses (PRISMA) Guidelines. The search was run in four databases: MEDLINE, Embase, CINAHL and EconLit. Full economic evaluations of genomic technologies at any stage of cancer care, and published after 2018 and in English, were included for data extraction. Results The review identified 137 articles that met the inclusion criteria. Most economic evaluations focused on the prevention and early detection stage ( n = 44; 32%), the treatment stage ( n = 36; 26%), and managing relapsed, refractory or progressive disease ( n = 51, 37%). Convergent cost-effectiveness evidence was identified for the prevention and early detection of breast and ovarian cancer, and for colorectal and endometrial cancers. For cancer treatment, the use of genomic testing for guiding therapy was highly likely to be cost effective for breast and blood cancers. Studies reported that genomic medicine was cost effective for advanced and metastatic non-small cell lung cancer. There was insufficient or mixed evidence regarding the cost effectiveness of genomic medicine in the management of other cancers. Conclusions This review mapped out the cost-effectiveness evidence of genomic medicine across the cancer care continuum. Gaps in the literature mean that potentially cost-effective uses of genomic medicine in cancer control, for example rare cancers or cancers of unknown primary, may be being overlooked. Evidence on the value of information and budget impact are critical, and advancements in methods to include distributional effects, system capacity and consumer preferences will be valuable. Expanding the current cost-effectiveness evidence base is essential to enable the sustainable and equitable translation of genomic medicine.

Year:

2025

Aims The Fontan procedure has revolutionized care for individuals born with single-ventricle heart disease, with over 80% of patients surviving into adulthood. This study aimed to estimate the long-term health-related quality-of-life (HRQoL) experienced by patients and families. Methods and results Patients, parents, and siblings were recruited through the Australian and New Zealand Fontan Registry and self-reported their HRQoL the Child Health Utility 9D index for children and EuroQol 5-Dimensions for adults. Responses included 125 patients, 69 siblings, and 144 parents. Child patients reported more sadness, challenges with school and homework, and problems joining in activities, resulting in a lower HRQoL summary score compared with the general child population (0.74 vs. 0.80, P = 0.03). Adult patients reported more problems with anxiety and depression, usual activities, and self-care. While 60% of adult patients reported a summary score comparable with the general population, the 40% of adult patients who perceived their heart condition as serious reported lower HRQoL (0.77 vs. 0.90, P = 0.01). Child siblings experienced more tiredness and annoyance, while adult siblings reported more anxiety and/or depression; however, total HRQoL summary scores did not differ from the general population. Parents’ HRQoL was comparable with the general population. Conclusion Overall, child patients, and adult patients who perceived their heart condition as serious, reported lower HRQoL than the general population. Siblings reported concerns in specific HRQoL domains. The reported utility scores can serve as references for the Fontan population and their family members, as well as formal inputs for economic evaluations of interventions to assist with resource allocation decisions.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Background Moderate-late preterm infants born at 32–35 completed weeks’ gestation constitute a large proportion of all preterm births (< 37-week gestation), yet they are not well represented in the newborn resuscitation literature. Preterm infants often receive respiratory support in the delivery room, and recommendations exist to guide the use of supplemental oxygen when providing this support. However, there are minimal data regarding the best initial supplementary oxygen concentration for moderate-late preterm infants requiring respiratory support at birth, resulting in practice variation. The aim of this trial is to compare initial supplementary oxygen concentrations of 30% and 21% (air) in preterm infants of 32–35 weeks’ gestation who require respiratory support in the delivery room, with a primary outcome of the need for ongoing respiratory support upon leaving the delivery room. Methods This is a prospective, unblinded, multicenter, cluster-randomized, crossover trial in Australian maternity hospitals comparing initial supplementary oxygen concentrations of 30% and 21% (air) in moderate-late preterm infants who require respiratory support at birth. Eligible infants are those born from 32 + 0 to 35 + 6 weeks’ gestation without major cardiorespiratory or craniofacial anomalies, who are receiving active care, and who receive respiratory support in the delivery room within the first three minutes after birth. The primary outcome is the need for ongoing respiratory support upon leaving the delivery room. The trial will recruit a minimum of 1200 infants from at least 20 study sites in Australia using a waiver of consent process. Discussion The AIROPLANE trial is a pragmatic study in an underrepresented population using a novel study design. It will be the first randomized study of initial supplementary oxygen concentration during respiratory support in the delivery room to exclusively recruit moderate-late preterm infants. The results will address an important evidence gap and will inform future international guidelines. Trial registration Australian New Zealand Clinical Trials Registry ACTRN12621001267842. Registered on 20th September 2021.

Year:

2025

Introduction Infants born very preterm (VPT, <32 weeks’ gestation) are at increased risk for neurodevelopmental impairments including motor, cognitive and behavioural delay. Parents of infants born VPT also have poorer mental health outcomes compared with parents of infants born at term. We have developed an intervention programme called TEDI-Prem (Telehealth for Early Developmental Intervention in babies born very preterm) based on previous research. TEDI-Prem aims to improve neurodevelopmental outcomes and parental well-being in children born VPT. Here we present the protocol outlining a multicentre, pragmatic, parallel-group, randomised controlled trial to determine the efficacy of TEDI-Prem plus usual care, compared with usual care alone. Methods and analysis We will recruit 466 VPT infants from the neonatal units of five hospitals in Victoria, Australia. Participants will be randomised, stratified by site of recruitment and multiple births, to TEDI-Prem plus usual care or usual care alone. The TEDI-Prem intervention programme involves 13 sessions across three phases. Phase 1 commences in the neonatal unit with four face-to-face sessions with parent/s and a physiotherapist/occupational therapist. Once discharged from the hospital, sessions across phases 2 and 3 (six and three sessions, respectively) continue via telehealth until infants are 12 months’ corrected age (CA). The primary outcome is the Bayley Scales of Infant and Toddler Development-fourth edition (Bayley-4) Motor Composite Score at 12 months’ CA. Secondary outcomes address other neurodevelopmental domains (Bayley-4 cognitive and language composite score; Infant Toddler Social Emotional Assessment), parental mental health (Depression Anxiety and Stress Scale 21), parent–child interaction (Emotional Availability Scale) and programme cost-effectiveness which encompasses parent quality of life (Short-Form Six-Dimension Quality of Life) and child quality of life (EuroQol Toddler and Infant Populations measure) at 12 and 24 months’ CA. Mean differences between groups will be examined using linear regression for continuous outcomes and logistic regression for binary outcomes. All models will be fitted via generalised estimating equations to account for multiple births and adjusted for the hospital sites. Ethics and dissemination This trial has Royal Children’s Hospital Human Research and Ethics Committee approval (HREC/67604/RCHM-2020) with specific site approval for all participating sites. Findings will be disseminated through peer-reviewed publications, conference presentations, digital and print media and to participants. Trial egistration number This trial is registered with the Australian New Zealand Clinical Trials Registry (ACTRN12621000364875).

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (16)

Natalie Carvalho

University of Melbourne

AUSTRALIA
View details

Katherine Bates

University of Michigan

UNITED STATES
View details

Brett Manley

University of Melbourne

AUSTRALIA
View details

David Celermajer

Group Leader

University of Sydney

AUSTRALIA
View details

Alicia Spittle

University of Melbourne

AUSTRALIA
View details

Oliver Rivero-Arias

Professor of Health Economics

University of Oxford

UNITED KINGDOM
View details

Karin Du Plessis

Adjunct Associate Professor

Victoria University

AUSTRALIA
View details

Tianxin Pan

University of Melbourne

AUSTRALIA
View details

David Winlaw

Co-executive Director, Heart Center and Division Head, CV Surgery

Lurie Children's Hospital

UNITED STATES
View details

Anneke Grobler

Murdoch Childrens Research Institute

AUSTRALIA
View details

Vivienne Milch

Professorial Fellow

Flinders University

AUSTRALIA
View details

Aideen McInerney‐Leo

Research Leader

University of Queensland

AUSTRALIA
View details

Fanny Franchini

Senior Research Fellow

University of Melbourne

AUSTRALIA
View details

Yves d’Udekem

Chief of cardiac surgery

Children's National Health System

UNITED STATES
View details

Kate Marshall

University of Wollongong

AUSTRALIA
View details

Harriet Hiscock

Academic Lead, Transforming Healthcare

University of Melbourne

AUSTRALIA
View details